Noven Pharmaceuticals (NOVN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Noven Pharmaceuticals (NOVN)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Todd D. Wiener who wrote ()	8/12/1997 1:03:00 AM
From: Todd D. Wiener	of 66

NOVN is a small company with a big future. The second half of 1997 should be very exciting, as NOVN's revenues and earnings begin to increase sequentially. RPR and Novartis will resume their purchases of NOVN's transdermal estrogen patches for HRT. And DentiPatch, NOVN's transoral lidocaine patch, may begin to replace injected anesthetics in dental procedures as it is lauched throughout the U.S. The company is developing several other uses for its technology, including transoral delivery of nitroglycerine, insulin and other chemicals and medications. Also, NOVN has several phase 1 and 2 trials currently in progress. Just yesterday, RPR filed an NDA for NOVN's transdermal combination estrogen/progestogen patch. I believe that NOVN has significant potential, both as a company and as a stock. The current stock price ($10.625) does not account for the potential success of DentiPatch, or the success of NOVN's extensive product pipeline. While there is risk in this investment, the stock offers the potential for substantial returns over the next several years. Let the discussion begin. Todd

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext